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Abstract:
Background:
Many randomised control trials and systematic reviews have examined the benefits of glucocorticoids for the treatment of croup in
children, but they have reported mainly on dexamethasone as an oral treatment for croup. No systematic reviews have examined
prednisolone alone.
Aim:
To determine in a systematic review of the literature whether a single dose of oral prednisolone is as effective as a single dose of
dexamethasone for reducing croup symptoms in children.
Search Strategy:
A detailed  search  was  conducted  on  the  following  databases:  CINAHL,  MEDLINE EBSCO,  MEDLINE,  OVID,  PubMed,  The
Cochrane Library, ProQuest, EMBASE, JBI, Sum search, and OpenGrey. Study authors were contacted.
Selection Criteria:
Randomised  Controlled  Trials,  clinical  trials  or  chart  reviews  which  examined  children  with  croup  who  were  treated  with
prednisolone alone, or when prednisolone was compared to a dexamethasone treatment and the effectiveness of the intervention was
objectively measured using croup scores and re-attendance as primary outcomes.
Data Collection and Analysis:
Following  PRISMA  guidelines  for  systematic  reviews,  relevant  studies  were  identified.  Scores  were  graded  agreed  by  two
independent reviewers using QualSyst.
Main Results:
Four studies met the inclusion criteria, but were too heterogeneous to combine in statistical meta-analysis. The result suggests that
although prednisolone appears as effective as dexamethasone when first  given, it  is  less so for preventing re-presentation. Trial
sample sizes were small, making firm conclusions difficult, however, a second dose of prednisolone the following day may be useful.
More research including cost-benefit analysis is needed to examine the efficacy of prednisolone compared to dexamethasone.
Keywords: Systematic review, Croup, Prednisolone, Dexamethasone, QualSyst, Corticosteroids.
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1. BACKGROUND
1.1. Prevalence of Croup
Croup or acute laryngotracheobronchitis is a common illness, which is most prevalent in young children between
the ages of 6 and 36 months, and has a large impact on health services. Croup is a common reason for accessing out-of-
hours  care  [1]  and  is  a  frequent  cause  behind  hospital  admissions  of  children  between  6  months  and  3  years  [2].
Admission rates of children assessed in outpatient settings range from 1.5% to 31% of the cases seen, depending on
hospital admission policies, the severity of the disease, and the social and other characteristics of the population being
assessed [3].
Usually appearing as a self-limiting illness, croup often causes parental anxiety, and imposes a large burden on
healthcare systems [3]. However, most symptoms of mild croup usually resolve within 48 hours. In some cases, severe
upper-airway  obstruction  can  lead  to  respiratory  failure  and  arrest,  but  such  cases  are  rare  [4].  Most  children  are
managed  through  primary  care,  with  less  than  5% requiring  hospitalisation,  among  which  1-3% require  ventilator
support in an intensive care setting [5].
The economic burden imposed by croup has been demonstrated in a study by Rosychuk et al, [6] which reported
that there were 27,355 emergency admissions at accident and emergency settings in the province of Alberta, Canada,
for episodes of croup over a six-year period. The incidence of croup among children is reported at three children per one
hundred children in the United States in a typical year, with as many as 6% of those children requiring hospitalisation
[6]. Figures are similar in Australia, with croup affecting 3% of children under 6 years of age in a typical year [7]. One
retrospective Belgian study found that 16% of children aged 5-8 years had suffered from croup at least once and 5% of
those children had experienced recurrent croup (at least 3 episodes) [8].
Respiratory tract infections such as croup in children are one of the most common reasons for parents consulting
health  professionals,  with  viral  croup  being  the  most  common  form of  airway  obstruction  in  children  between  six
months  to  six  years  [9].  One long-term prospective  cohort  study suggested  that  croup occurred most  commonly in
children aged between 6 months and 3 years, but can also occur in children as young as 3 months and as old as 12-15
years [10].
1.2. Aetiology of Croup
Croup is more prevalent during autumn and early winter with major peaks coinciding with Para-influenza activity
often observed in October [11]. The following are the most common viral causes for croup: Para influenza type 1 and 2,
Influenza A, adenovirus, rhinovirus, respiratory syncytial virus and, mycoplasma pneumonia [12]. The Para influenza
virus type 1 accounts for approximately half of all cases throughout the winter [13]. These common viruses can affect
the  narrowest  part  of  the  airway  called  the  subglottic  region,  and  even  small  amounts  of  swelling  or  oedema  can
significantly increase the difficulty involved in breathing in young children [14]. As oedema of the proximal airway
epithelium progresses, inspiratory stridor and signs of breathing difficulties supervene [15]. This is due to the small
children having a very narrow larynx such that even a small decrease in airway radius can cause a large decrease in
airflow, leading to croup symptoms. Commonly between the ages of 1 and 3 because as children become older, their
breathing tube becomes firmer and wider and so the incidence of croup reduces [1].
Several  other  factors  may  make  a  child  more  likely  to  suffer  with  croup.  This  may  be  due  to  the  pre-existing
narrowing of the upper airway, subglottic stenosis (congenital or secondary to prolonged neonatal ventilation) or Downs
syndrome  [16].  Furthermore,  Alshehr  et  al.,  [17]  suggests  that  there  is  increasing  evidence  that  an  immunological
component for acute croup coincides with high titres of both Para influenza virus and specific immunoglobulin E in the
children’s nasal secretions. This may explain why croup will often affect atopic children who may already suffer with
asthma or eczema.
1.3. Corticosteroids in The Treatment of Croup
Oral  corticosteroids  act  on  the  subglottic  oedema  and  obstruction  by  decreasing  capillary  permeability  and
suppressing localised inflammation [18]. The exact mechanism of the administration of steroids in croup is not fully
understood [13] but it  is known that glucocorticoids also have vaso-constrictive effects that may contribute to their
clinical  actions  by  resulting  in  reduced  airway  oedema,  less  micro-vascular  leakage,  and  reduced  airway  mucus
production [19]. When used as croup treatments, glucocorticoids reduce the inflammation in the airway obstruction as
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quickly as one hour after administration [20]. A reduction in these inflammatory properties leads to a decrease in the
difficulty of breathing for the child.
Prednisolone or dexamethasone may be given orally or intramuscularly, both of which have superior efficacy to
placebo but oral preparations of corticosteroids are the preferred mode of administration in most paediatric emergency
departments because they are inexpensive, easy to administer, readily available, and result in measurable improvements
[21]. Systemic corticosteroids (dexamethasone, prednisolone) are the treatment of choice because benefits can be seen
in patients with all levels of croup severity [22].
The half-life  of  dexamethasone is  approximately  double  of  that  of  prednisolone,  and estimates  range from oral
dexamethasone  having  an  effective  half-life  of  48  hours,  compared  with  the  24  hours’  half-life  of  prednisolone  to
prednisolone’s relatively short-acting half-life of 12-36 hours, thereby requiring daily dosages [23, 24]. In comparison,
prednisolone is up to six times less potent than dexamethasone with hypothalamic-pituitary-adrenal axis suppression in
prednisolone lasting 1.5 days against 2.5 days in case of dexamethasone [20]. Extensive evidence in the form of primary
studies [14, 25 - 28,] shows that the administration of steroids in a single dose of corticosteroid lessens the risk of a
child needing hospital admission or re-presenting for further medical care. Meta-analysis of 24 randomised controlled
trials [25] reviewed nine methodically satisfactory trials, five favourable and four unfavourable, involving steroids in
the treatment of croup, which supported the use of steroids for children who were ill enough to be hospitalised. Among
the  included  studies,  dexamethasone,  budesonide,  and  prednisolone  were  all  included  and  the  results  were
amalgamated, which made it not possible to identify each arm of the group, instead they were examined as a whole
cohort. This meta-analysis concluded that glucocorticoids were effective at improving symptoms within six hours, for
up to 12 hours [25]. A further meta-analysis [28] reports main outcomes, clinical improvement, and croup scores of the
children at 12 and 24 hours post treatment and the incidence of endotracheal intubation, and provided a reliable estimate
of the impact of steroid therapy on the morbidity associated with croup at that time. Reported data from the ten clinical
trials  involving  children  with  severe  croup  showed  that  corticosteroid  treatment  decreased  endotracheal  intubation
fivefold. Children with mild croup only require reassurance, suggesting that at that time there was no evidence that
steroids have a place in management in this group, although a single dose of prednisolone is probably appropriate for
children with ‘stridor at rest’, but no recession [29].
Evidence clearly supports the use of oral, parenteral, or nebulised corticosteroids for children admitted with croup
[3, 14] and it has been demonstrated that the glucocorticoid treatment of croup has consistently led to improvements in
symptoms so much so that they infer that studies involving just dexamethasone are unwarranted as there is so much
evidence that it works, but there is a lack of direct comparison studies of dexamethasone versus prednisolone, with very
little literature available [30]. However, concerns exist about using oral steroids to treat croup, as these types of drugs
with their long serum half-lives could have sustained effects on multiple systems, and may reduce the immune function
[17]. One study [31] reports that four or more courses of oral prednisolone during childhood may have adverse effects,
including  an  increased  fracture  risk,  although there  are  no  relevant  comparison  studies.  It  appears  that  the  risks  of
administering single-dose corticosteroids are very low, but should be considered in children with diabetes mellitus,
children  exposed  to  varicella  virus,  children  at  risk  of  bacterial  super  infection  (i.e.,  those  who  are
immunocompromised), or have gastrointestinal bleeding [32]. The small benefits of steroids for mild croup have been
discussed as not worth the risk of serious adverse effects which can be seen in as many as eight children per thousand
who are treated with steroids [33]. A Cochrane review [34] disputed such safety concerns, providing comprehensive
safety  data  on  the  use  of  steroids  in  2,214  children  with  acute  respiratory  conditions,  including  croup  and  other
respiratory  problems  such  as  asthma,  concluding  that  the  results  showed  no  difference  between  children  receiving
steroids versus a placebo 1.5% V 1.8% (gastrointestinal bleeding and or abdominal pain in the steroid group versus the
placebo group). Gastrointestinal bleeding would be unlikely in otherwise healthy children [12].
2. RATIONALE FOR THIS SYSTEMATIC REVIEW
In  the  United  Kingdom,  there  is  currently  a  nationwide  difficulty  in  obtaining  dexamethasone  syrup  for  the
treatment of croup in children, which has led to the default prescription of the only other alternative, prednisolone. In
some areas in the UK, clinicians have been unable to obtain dexamethasone syrup for some time, and dosing regimens
vary between emergency, primary and secondary care settings. Many children with croup are being treated with a one-
off  dose  of  prednisolone,  although  a  two  or  three-day  treatment  at  varying  doses  has  also  been  noted,  with  the
prescribing of prednisolone appearing to be used in a similar way to treating exacerbations of asthma in children, with
up to a three-day course; however, there is confusion in the available literature about what dose of prednisolone to give
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and for how long. It is not clear what the most therapeutically effective range is and this lack of clarity drives the need
for this review. Commercially, at the time of writing, oral dexamethasone was only available locally as a tablet, which
makes it unsuitable for young children [5]. Hospital pharmacists can make it up in the form of a dexamethasone elixir,
but that is expensive and not available in general practice [35]. Prednisolone has pharmacokinetic properties similar to
dexamethasone,  and  has  the  significant  advantage  in  that  it  is  commercially  available  in  a  liquid  preparation.
Prednisolone can be prescribed as a soluble tablet; which parents can crush into a little juice or water to give to their
children.
In Australia, where a majority of the major croup studies have taken place, oral dexamethasone suspension is only
available in hospitals and not at commercial pharmacies, thus necessitating the use of prednisolone in primary care
settings [16]. Liquid dexamethasone preparations are also not available in many counties, including Germany and most
other European countries [36].
3. MATERIALS AND METHODS
The  purpose  of  systematic  reviews  is  to  determine  effectiveness  and  involve  the  comparison  of  two  or  more
interventions  [37].  Systematic  reviews  of  other  types  of  evidence  can  facilitate  decision-making  in  areas  where
randomised controlled trials (RCTs) have not been performed or are not appropriate [38]. They are considered the best
way to synthesise the findings of several studies, all investigated in the same way [39] noting that systematic reviews
have become the gold standard for evidence-based decision-making, and provide building blocks for clinical practice
guidelines [40]. Systematic reviews are essential to summarise evidence relating to efficacy and safety of healthcare
interventions. With their synthesis of a large body of evidence they aid policy makers and professionals to keep up-to-
date with advances [39].
Systemic reviews and meta-analysis provide the highest level of evidence. However, poor reporting may reduce
their utility. The PRISMA statement was developed to help authors report their systematic reviews adequately [41] and
has been incorporated into this systematic review. There are several approaches to this process but all follow similar
steps, which are identifying the problem, finding the research, and determining the level of evidence [42]. The PRISMA
statement aims to improve reporting focussing on systematic reviews of RCTs and systematic reviews that  need to
adhere to rigorous methodology to produce clear and unbiased results [43].
Centre  for  Reviews  and  Disseminations  (CRD)  [44]  recommend  that  before  undertaking  a  systematic  review,
researchers should check whether there are existent or on-going reviews on their area of interest, and whether a new
review is justified, beginning the process by searching the Database of Abstracts of Reviews of Effects (DARE). To
date, there are no other systematic reviews that specifically look at the issues of whether prednisolone is as effective as
dexamethasone for this very common childhood complaint, which makes this work important. Yet it is acknowledged
that there are several systematic reviews of all treatments for croup, which include prednisolones usage, and some of
which  compare  prednisolone  to  dexamethasone  [14,  20,  25  -  28].  However,  no  new systematic  reviews  have  been
conducted since 2011.
3.1. Review Aims
To investigate the comparative effectiveness at reducing croup in children under 12 years of oral dexamethasone
and prednisolone, and to examine the optimum dose of prednisolone to prevent relapsing symptoms and re-admission.
3.2. PICO
Using PICO helps structure a search, and should include the main terms relating to the research question [45]. PICO
is one of the tools that can assist in formulating research questions [44], and a clear concise question will make it easier
to generate the best available evidence [46]. The PICO developed for this systematic review is shown in (Table 1).
3.3. Population
The population for this study is children who have croup. The area of interest is the treatment or therapy of children
suffering with croup. The age range for this review is set at 3 months-12 years [1] as this is the most typical age bracket
during which children are affected. Gender is not a variable in this study, although it is noted that croup typically affects
more boys than girls.
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3.4. Intervention
The intervention will examine the use of prednisolone when used as a croup treatment in any severity of croup when
used in either isolation or placebo or when used as alternative treatment to dexamethasone.
Table 1. PICO employed in this systematic review.
P Patient, Population, or Problem How would I describe a group of patients similar to mine? Children with croup < 12 years of age.
I
Intervention, Prognostic Factor, or
Exposure
Which main intervention, prognostic factor, or exposure am I considering? Prednisolone or
dexamethasone
C
Comparison or Intervention (if
appropriate)
What is the main alternative to compare with the intervention? Studies that examine prednisolone
usage or compare prednisolone with dexamethasone
O
Outcome you would like to measure or
achieve
What can I hope to accomplish, measure, improve, or affect? Measured symptom reduction, dosages
and re-presentation rates.
3.5. Comparative Intervention
Only  studies  that  examine  prednisolone  as  a  stand-alone  treatment  for  croup,  or  compare  prednisolone  to
dexamethasone  will  be  used.
3.6. Outcomes
What is being measured is the reduction in symptoms in the children, based on the use of either drug, but only when
compared to each other, i.e. primary outcomes are changed in clinical croup scoring from baseline to time in the future
as defined by the researchers. Which drug they received, how much of it, and for how they long and which the key
outcomes were measured. Also return visits and readmissions are secondary outcomes, which are measured.
3.7. Time Frame
2000-2016.
3.8. Review Questions
The questions that this systematic review seeks to answer are:
1. Is a single dose of oral prednisolone as effective as a single dose of dexamethasone at reducing croup severity
score in children under 12 years?
2. What is the optimum dose of prednisolone to prevent relapsing symptoms and re-admission?
3.9. Search Strategy
A methodical approach based on PRISMA guidelines for undertaking reviews using electronic databases to search
the  literature,  which  was  supplemented  by  hand  searching  and  cross  referencing.  The  search  was  based  on  a  pre-
determined series of keywords which are related as follows: Croup AND Prednisolone AND dexamethasone. Fig. (1)
shows the combined results of the searches in a PRISMA flow diagram.
The time period is selected on the basis that around 2000 onwards, the intervention of using steroids became more
widespread with some of the biggest steroid trials in mild croup being conducted in the early part of that decade.
3.10. Databases
The following databases were searched:
CINAHL (Cumulative Index of Nursing and Allied Health Literature);
MEDLINE EBSCO;
MEDLINE OVID;
PubMed;
ProQuest;
EMBASE;
Joanna Briggs Institute;
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SUM search;
OpenGrey;
Cochrane Database of Systematic Reviews (CDSR);
Cochrane Central Register of Controlled Trials (CCRCT);
BIOSIS and Health Services/Technology Assessment (HSTAT) and
The National Research Register.
In addition, AE wrote to trial authors of studies, and the two who replied both reported that no unpublished results
were available at that time.
Fig. (1). Combined results of the searches in a PRISMA flow diagram.
11 
CINAHL plus           13    PubMed                             215 
 
Medline Ebsco       15     Cochrane Library             70 
 
Medline Ovid          130    JBI                                         0 
 
Embase         20                                           Sum search                        2 
 
Open Grey            0       (N= 465)   
         Records after    
duplications removed  
                  (N= 23)  
   Records screened  
 
               (N=442)  
 Six articles   Full text 
retrieved  
                (N=6)  
Hand searching 
Bibliography  
                  (N=0) 
 Exclusions 
 
Did not examine 
prednisolone or 
dexamethasone in 
relation to Croup.  
Used other drug 
therapies such as 
nebulised adrenaline 
or budesonide. 
Examined rectal dosing 
of prednisolone.  
Children admitted to 
an ITU setting. 
Children with illnesses 
other than croup. 
Studies examining 
severely ill children or 
children with a 
structural abnormality 
of the upper 
respiratory tract. 
Articles excluded after 
quality assessment   
                      (N=0) 
 
 Records 
excluded (as 
they were not 
examining 
croup)  
 
(N=437)  
 Two full text 
articles 
(systematic 
reviews) 
excluded  
 
( N= 2)  
Studies Included in the quantitative synthesis 
                                        (N=4)  
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3.11. Inclusion and Exclusion Criteria
Inclusion:
RCTs, Case controlled studies and cohort studies.
Studies needed to be published in English and full text available.
Content  relates  directly  to  croup  and  its  treatments  involving  prednisolone  alone  or  in  comparison  to
dexamethasone.
Publication of a research study within a peer-review journal.
Research must be related to the treatment of croup in children.
Research must include prednisolone alone or in comparison to dexamethasone, noting that oral or intra-muscular
treatments were the preferred methods of treating croup for this systematic review.
Exclusion:
Studies that did not examine prednisolone or dexamethasone in relation to croup.
Studies that used other drug therapies such as nebulised adrenaline or budesonide.
Studies that examined rectal dosing of prednisolone.
Studies that just examined dexamethasone.
Studies pertaining to cases when treatment was such that children were admitted to an Intensive Therapy setting.
Studies  involving  children  with  illnesses  other  than  croup,  for  example  upper  respiratory  tract  infections,
asthma, or bronchiolitis.
Studies examining severely ill children or children with a structural abnormality of the upper respiratory tract.
3.12. Screening
A two-stage process was used during screening. Stage one involved screening the article and the abstract against the
inclusion criteria. If there was uncertainty over the suitability of the publication, the full text of the article was assessed.
Potential usefulness was identified from the abstracts by the initial search for appropriateness to the study question.
Relevance  was  based  on  the  review  of  the  title  and  the  abstract.  Two  studies  were  excluded  because  they  were
systematic  reviews.  Stage  two  involved  screening  of  the  full  text  of  articles  against  the  inclusion  criteria.  Studies
examining rectal doses or the ones that examined children who were intubated were also excluded because they did not
appear relevant to study or its aims, and not did not seem applicable to primary care or general practice.
3.13. Quality Assessment
Following the full-text  selection,  the studies  were assessed for  methodological  quality.  Systematic  reviews rely
substantially on the assessment of the methodological quality of the individual trials, and quality assessment allows
means that papers can be excluded papers or weighted in the analysis phase of the review, and to determine whether
research quality makes a difference to the nature of the findings [47, 48]. The quality of the randomised controlled
studies and the chart reviews were assessed using the QualSyst tool for quantitative studies. The scoring system is peer-
reviewed  [38]  and  based  upon  established  quality  assessment  tools  for  quantitative  studies.  To  use  the  QualSyst
assessment, each study is scored according to the degree to which they meet 14 criteria (yes = 2, partial = 1, No = 0).
Items not applicable to a particular study design can be marked N/A and can be excluded from the total summary score
[49].
In this systematic review, one reviewer (AE) and another author (GW) reviewed the studies independently, and both
graded the quality  of  each paper  to  be included.  Both authors  agreed on the same quality  scoring of  all  the  papers
included.  All  the  studies  selected  met  the  minimum threshold  of  a  summary  score  of  0.6.  Four  studies  met  all  the
criteria for inclusion.
4. RESULTS OF THE SYSTEMATIC REVIEW AND CRITICAL APPRAISAL
4.1. Heterogeneity
In  the  context  of  systematic  reviews,  statistical  meta-analysis  of  findings  is  not  always  possible.  Meta-analysis
should only be considered when a group of studies is sufficiently homogeneous in terms of participants, interventions,
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and outcomes in order to provide a meaningful  summary [50].  Since all  of  the studies included measured different
outcomes, used different drug doses, and differing lengths of treatment time, it was not possible to pool the collective
results and so a narrative approach was taken. This is outlined in Table 2. Narrative synthesis aims to summarise and
explain the findings of the synthesis primarily relying on the use of words and text to summarise (rather than statistics)
and should encompass the analysis of the relationship within and between the studies, as well as provide an assessment
of the evidence [51].
4.2. Randomisation and Blinding
All of the randomised controlled trials in this review reported sufficient information for them to be assessed as
adequately randomised with adequate concealment of allocation and blinding of the participants and researchers [56].
Allocation bias can occur when the measured treatment effect differs from the true treatment effect because of how
participants were selected into the intervention or control groups [57]. To avoid this, patients should remain unaware of
which  treatment  is  being  given  until  the  study  is  completed  [58],  and  this  was  achieved  by  double  blinding  the
participants and the researchers in all the RCTs. It must be noted that allocation concealment is completely different
when blinding the former, which seeks to eliminate selection bias during the process of recruitment and randomisation,
whereas blinding the latter seeks to reduce performance and ascertainment bias after randomisation [59].
Table 2. Relative heterogeneity of the included studies.
Author
Patient Group and
Age
Study Design Outcomes Key Results Study Weaknesses
[52]
Sparrow
and
Geelhoed,
2006.
Children aged 3
months to 142
months old
presenting to a
single emergency
department with
mild to moderate
croup.
Randomization and
blinding
Double blind,
randomised equivalence
study.
Sample size and
attrition
133. No attrition
Medication dosages
Patients received a
single dose of 0.15
mg/kg dexamethasone
0.6 dexamethasone or 1
mg/kg prednisolone.
Lengths of time of
administration
Single dose of
prednisolone, 1 mg/kg,
matched for potency
with a single dose of
dexamethasone in
children with mild to
moderate croup.
Primary outcome was the
magnitude and rate of reduction in
Westley croup score.
Clinical observations at 30 minutes
after administration of steroid;
hourly for the next four hours and
four hourly thereafter until
discharge. Criteria for discharge
home were minimal stridor or
chest wall retractions—that is, a
croup score of 1 or 0.
Re-attendance at medical care
within 7-10 days.
Responses to treatment:
Five out of 68 (7%)
children who had
received dexamethasone
returned for medical
care versus 19/65 (29%)
children who had
received prednisolone.
No significant
difference between the
three groups in
magnitude or rate of
Westley score
reduction.
Included patients up to the
age of 12 years, although
very uncommon for older
children to be affected.
Exclusion criteria included
prior administration of
steroids, non-English
speakers and no access to
telephone. Small numbers.
[53] Fifoot
and Ting,
2007
Children 6 months
to 6 years
presenting to a
single emergency
department with
mild or moderate
croup
Randomization and
blinding
Double blind,
randomised trial.
Sample size and
attrition
99 children with 86
patients followed up by
telephone (87%).
Medication dosages
Patients were
randomised to receive 1
mg/kg prednisolone,
0.15 mg/kg
dexamethasone or 0.6
mg/kg dexamethasone.
Lengths of time of
administration
Single dose.
Primary outcome measures were
the magnitude and rate of
reduction in Westley croup score,
rate of return for medical care with
ongoing croup, and further
treatment with steroids in the week
following index presentation.
Secondary outcome measures were
the proportion of subjects requiring
admission or salvage therapy, such
as nebulized adrenaline, during
index presentation.
Follow-up by telephone interview
at 7 days, Taussig score.
Responses to treatment
No significant
difference in admission
rates, duration of
symptoms or
attendances. No
significant difference
between treatment
groups.
Small sample size. Large
number of eligible patients
not recruited. Primary
outcome over short time
period.
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Author
Patient Group and
Age
Study Design Outcomes Key Results Study Weaknesses
[54]
Garbutt et
al, 2013
Children aged 1-8
years presenting to
primary care offices
with mild or
moderate croup in
the USA.
Randomization and
blinding
Double blinded
randomised comparison
trial
Sample size and
attrition
Eighty-seven children
randomised with 98%
follow up at 11 days.
Medication dosages and
lengths of time of
administration
Prednisolone 2mg/ kg
per day for 3 days
versus one dose of
0.6mg dexamethasone
and two placebo doses
Additional health care within 11
days of randomization
assessed by self-report Telephone
Out Patient score.
Secondary outcomes included:
duration of croup symptoms;
disturbed sleep; parental stress;
adverse events including sleep
problems, mood changes, headache
or dizziness, nausea, stomach pain,
and secondary infections.
No difference in
outcomes of either
group for child or
parent.
Small numbers.
People with no telephone
and lacking English
spoken language were
excluded.
[55] Parker
et al, 2004
Children aged 4
months to 11 years,
median age 2 years
presenting in an
emergency
department with
mild or moderate
croup
Retrospective chart
review.
Randomization and
blinding
Not undertaken
Sample size and
attrition
188 eligible for analysis
from 814 patients coded
as croup.
Medication dosages
1mg/kg prednisolone.
Lengths of time of
administration
Not specified but
implicitly single dose
only
How long stridor at rest persisted
after administration of
prednisolone 1mg /kg.
Westley and Geelhoed croup
scores.
To determine whether children
with mild croup
had a more rapid
resolution of stridor at rest.
Average length of time
from SAR to cessation
was 6.5 hours.
Children with mild
croup improved quicker
although this is reported
as not clinically
significant.
Retrospective chart
reviews rely on
completeness of
contemporaneous data
entry. Inter rater reliability
reported as moderate. Lack
of power calculation
There  was  no  selection  bias  in  the  RCTs,  which  is  concerned  with  systematic  differences  arising  between  the
sampling population and the sample drawn. Selection bias occurs when the subjects studied are not representative of the
target  population about  whom the conclusions are to be drawn [60].  All  the children were randomly selected upon
entering the trial from either the emergency department or the selected primary care offices, although they needed to
have similar baseline observations and follow-up ability as this was important. Selection bias as one of the major types
of bias that can impair the results of a randomised control trial but due to the nature of the design of a trial it can, and
should be, avoided [61]. Randomised control trials have the unique advantage of using randomisation as a method of
determining patient allocation to treatment, which eliminates selection bias if correctly executed notes that bias can
cause estimates of association to be either larger or smaller than a true association [62, 63]. Also randomised control
trials rest on internal validity, which is based largely on the power of randomisation, to ensure that the only difference
between two treatment arms is their exposure to the treatment of interest [63].
All of the studies clearly reported the number and the ages of the children who participated in the studies as well as
the  inclusion/exclusion  criteria.  In  all  of  the  RCTs,  the  studies  reported  co-interventions.  For  example,  use  of
budesonide or adrenaline, or exclusion of children due to the severity of the illness. In fact, all of the studies reported
dropouts, or children who needed intubation, or those whose parents withdrew consent.
4.3. Sample Sizes and Attrition
New research studies should seek preliminary evidence that the intervention is likely to be beneficial (from other
similar  studies).  Such  information  is  needed  to  estimate  sample  sizes  and  justify  the  expense  of  a  trial  [58].  Since
information  is  based  on  previous  studies,  a  size  calculation  can  be  made  based  on  whatever  clinically  meaningful
difference is considered important to be detected [64].
The three trials used the intention to treat approach [52 - 54]. All of these studies appeared to report all the outcomes
initially stated as their objectives. This means that patients were normally analysed within the group to which they were
(Table 2) contd.....
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allocated,  irrespective  of  whether  they  continue  to  experience  the  intended  intervention  or  not  (intention  to  treat
analysis) [58].
The size varied in the trials but was generally small (under 200). However, to account for heterogeneity, RCTs need
to be quite large to achieve statistical significance. Garbutt et al. [54] acknowledge recruiting issues in their trial with
authors being unable to recruit their target sample of 200 patients, so much so that they remarked that there is a failure
to demonstrate a significant difference between the two study drugs because of inadequate power associated with the
small  sample  size  [54].  Like  Garbutt  et  al.’s  trial  [54],  Fifoot  and  Ting  [53]  found  that  their  trial  was  powered
sufficiently to give primary outcome of reduction in the Westley croup score. However, they had insufficient numbers
to prove that there would be no difference in representation between the groups’ secondary outcomes. Also, inflation
effect can be present in small low-powered studies, which can only detect effects that happen to be large [65]. Parker et
al. [55], only analysed data from 188 children using descriptive statistics but did not include a power calculation for
their trial. Every retrospective chart review requires a statistical power analysis to determine the appropriate sample
size. Calculating this appropriate sample size is a necessary component in all research proposals and is dependent on the
statistical tests used in the study [66].
Without detailed information regarding the sample size calculation used when publishing papers type II statistical
errors  cannot  be discounted [67].  Relatively large samples  obtained by probability  or  non-probability  sampling are
generally used for quantitative theory-testing research designs [42] as seen in the larger studies. Researchers have an
ethical  responsibility  to  recruit  an  adequate  size  for  their  trials  [42],  but  it  is  unethical  to  include  more  research
participants than are actually needed to obtain accurate data [68]. The minimum accepted level is considered to be 80%,
which means there is an eight in ten chance of detecting a difference of the specified effect size [69]. Usually, most
studies accept a power of 80%. This means that it is accepted that one in five times (that is 20%) real difference will be
missed. Low statistical power (because of the low sample size of studies, small effects, or both) negatively affects the
likelihood that a nominally statistically significant finding can actually reflect a true effect [65]. Power calculations tell
us the number of patients that are required in order to avoid a type I or a type II error [70]. Nearly all  quantitative
studies can be subjected to a sample size calculation [70]. The statistical power describes the probability that the study
will detect and affect where there is a genuine effect to be found [71]. Low power in the absence of other biases can
contribute to producing unreliable findings even when all other research practices are ideal [65]. If statistical power is
positively  correlated  with  the  sample  size  and  the  larger  sample  size,  researchers  will  be  enabled  to  find  smaller
differences,  which  are  statistically  significant  [72].  Many  null  studies  may  be  underpowered  to  detect  the  desired
difference due to a smaller sample size [67], in which case they will be statistically inconclusive and may make the
whole protocol a failure [72].  Some studies may be over-powered (too many participants)  and so it  is  important  to
achieve the correct balance [69].
Garbutt  et  al.  [54]  did  not  recruit  their  target  sample  of  200  patients  and  failed  to  demonstrate  a  significant
difference between the two study drugs, which was due to the inadequate power associated with the small sample size.
Their target sample size was 100 patients per group, based on the goal of estimating the number of children needed in
each arm of the trial to achieve a 95% confidence interval (CI). Fitfoot and Ting’s (2007) sample size calculations were
based on detecting a difference in the croup score baseline between the three intervention groups, and based on the
sample size, the difference was calculated at 33 patients per group.
Many children suffering from croup were not approached owing to the pressure on emergency staff over a busy
winter period [52]. Garbutt et al. [54] remarked that their results might not be generalizable to other communities as
they recruited patients from just one geographic area. Additionally, they did not present or discuss how representative
the patients were of all the patients with croup who were cared for at the study sites. Fifoot and Ting [53] suggest that
35.4%  of  eligible  children  were  missed,  again  due  to  the  high  clinical  activity  in  the  emergency  department.  The
researchers retrospectively analysed the data from these children to determine if they differed from those enrolled with
baseline characteristics being similar to the enrolled group. Parents who were contacted during the 1-10 days of the trial
may have been suggested  to  be  subject  to  participant  attrition.  This  can be  seen in  longitudinal  studies,  which can
introduce  systematic  bias  by  favouring  participants  who return  or  take  part  in  the  follow-up,  and  thus  increase  the
likelihood that those with complications will be underestimated because they did not take part [73].
Although randomised trials start as high-quality evidence, they can be down-rated if most of the relevant evidence
comes from studies that suffer from a high risk of bias [74]. Acknowledging there are many types of bias, these RCTs
all  appeared  to  have  inconsistencies  in  protocol  adherence  and  participants  dropping  out.  In  some  of  the  studies,
researchers  have  accounted  for  this  particular  bias.  Attrition  is  the  loss  of  randomly  assigned  participants  or
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participants’  data  [75].  This  will  ultimately bias  an RCT's  external  validity  by producing a  final  sample that  is  not
representative of the population sampled [76]. It was noted that there appeared to be bias in Garbutt et al trial [54] with
flaws  in  design  conducting  analysis  and  reporting  which  could  have  caused  the  effect  their  invention  to  be
overestimated [77]. Garbutt et al.’s trial [54] was the only trial, which reported the duration of use and self-reported
adherence, without differing between groups in their trial when measuring on-going symptoms. Such attrition means
that the balance in baseline characteristics for those randomised may not be maintained in the subsample that has the
outcome data [78]. However, the main evaluative strength of RCTs is that each group should be generally balanced in
all characteristics, with any imbalance occurring by chance [79]. Conducting RCTs in paediatric research is challenging
where recruiting more children than necessary risks unnecessary overexposure of children to inferior treatment, whereas
underestimating the size will produce inconclusive results [64].
4.4. Heterogeneity of Outcome Measures
All these randomised studies specifically outlined their intent to report on whether prednisolone was as effective as
dexamethasone or as in Parker et al.’s trial [55], how long stridor lasted for after the administration of prednisolone.
The trials all measured different outcomes although the methodology was the same in the randomised double-blinded
control trials and were all [52 - 55] explicit about their intention to study children of specific age groups and by specific
methods of data collection. Although the studies were conducted in different areas, only Garbutt et al.’s [54] trial was
based  around  primary  care  setting,  whereas  the  others  were  based  in  Emergency  Departments.  All  three  [52  -  54]
performed randomised double-blinded comparison trials of prednisolone versus dexamethasone, whereas Parker et al.
[55]  carried  out  a  retrospective  chart  review  questioning  how  long  stridor  at  rest  persists  in  croup  after  the
administration  of  oral  prednisolone.
There have been great improvements in patient’s clinical indices due to introduction of croup scoring systems [80].
A variety of scoring systems were used in these studies: the Westley croup Score [52, 55], the Taussig Croup Score
[53], the Geelhoed Score [55] and the Telephone Outpatient Score (TOP) [54]. Westley Croup score is the most widely
used and its validity and reliability have been well demonstrated [27]. Such heterogeneity in outcomes measures makes
analysing their results problematic and statistical meta-analysis impossible.
Only three of the scoring systems used in these studies have been shown to have reliability in independent studies.
The Westley Croup Score [81] has been evaluated its use with respect to inter-rater reliability, construct validity, and
responsiveness to change [5] and is the only method that has undergone validation and reliability testing and has shown
to be sensitive to important changes in a patient’s clinical status [14]. It performed well in all areas of assessment and
inter-rater reliability between three research assistants was assessed prospectively. The weighted kappa was 0.90 for the
total croup score, 0.47 for air entry, 0.93 for stridor and 0.87 for retractions [5]. Kappa was introduced as a measure of
agreement in form of a test of inter-rater reliability, which adjusts the observed proportional agreement to take into
account the amount of  agreement which would be expected by chance,  and represents the extent  to which the data
collected in the study are correct representations of the variables measured [82]. The Geelhoed score has demonstrated
inter-rater  reliability,  with a weighted kappa of above 0.85 in two independent studies,  indicating reasonable inter-
observer agreement [83]. The Taussig score, which was used by Fifoot and Ting [53], does not appear to have been
tested  for  validity  and  reliability  with  children  experiencing  croup  [84]  whilst  the  TOP  score  is  a  brief  telephone
outpatient  scoring  system  that  assess  the  presence  of  stridor  and  barky  cough  by  asking  parents  about  the  child’s
symptoms  in  the  last  24  hours  and  has  undergone  limited  testing  for  validity  and  reliability  [85].  Croup  scores
themselves  at  entry  point  to  trials  are  subject  to  both  inter-  and  intra-observer  variation  because  not  all  the  nurses
scoring the children are the same or it may be unlikely that the same nurse scores the same child later, meaning that the
formal establishment of inter-rater reliability is important, particularly if it has not been demonstrated.
4.5. Children’s Ages
The ages of the children in the studies varied. It is known that croup typically affects younger children, mostly under
the age of six years [5], although NICE [1] suggest that children as young as three months of age, adolescents, and very
rarely, even adults can be affected with croup. Croup diagnosed before the age of six months is uncommon and argues
that a child of less than six months with acute stridor should not be considered to have croup since croup is rare in
young babies [86]; even so two papers did enrol children from 3 months upwards [52, 55].
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4.6. Medication Dosages, Lengths of Time of Administration and Responses to Treatment
Further  analysis  of  the trials  showed that  they measured different  ranges of  drugs for  different  lengths of  time.
Sparrow & Geelhoed [52] examined a single dose of prednisolone versus a single dose of dexamethasone. Garbutt et al.
[54] measured three days prednisolone versus one day of dexamethasone (and two days placebo) Fifoot and Ting [53]
administered a single oral dose of either prednisolone at 1 mg/kg, and dexamethasone at 0.15 mg/kg as well as 0.6
mg/kg in this three arm trial. Parker et al. [55] calculated how long stridor persisted after a single dose of prednisolone.
Garbutt et al’s [54] trial is the only trial of its kind, which compared multiple doses of prednisolone with a single
dose of  dexamethasone,  something that  had not  been evaluated before.  Garbutt  et  al.  [54]  suggest  that  evidence to
support  the  treatment  of  croup with  a  one-off  dose  of  prednisolone  is  scant  but  it  offers  a  convenient  and  familiar
treatment  for  the  primary  care  management  of  croup,  as  it  is  commonly  used  for  in-office  treatment  of  asthma
exacerbations.  Although  prednisolone  has  not  been  widely  studied  there  is  no  reason  to  suppose  it  would  be  less
effective [3].
Further differences are noted in the information and outcomes that the researchers were interested in. Parker et al.
[55] collected patient demographics, croup scores on presentation to the emergency department, and the duration of
strider  at  rest  (SAR),  which  was  taken  to  be  the  time  from  administration  of  prednisolone  to  the  first  clear
documentation  that  SAR has  ceased  approximated  to  the  nearest  half  hour.  This  type  of  retrospective  study  relies
entirely on the completeness and accuracy of the data from the children’s medical records [87].
Sparrow and Geelhoed’s study participants [52] were also observed at 30 minutes after administration and then
hourly until the four-hour mark. In comparison, Garbutt et al.’s [54], main outcomes were unscheduled representations
to  medical  care  as  determined  by  telephone  follow-ups  at  7-10  days.  Other  secondary  outcome  measures  were
adrenaline (epinephrine)  use,  croup score,  and the time spent  in  the emergency department.  Fifoot  and Ting’s  [53]
trial’s primary outcomes were the severity and rate of reduction in the Westley croup score, rate of return for medical
care  with  on-going  croup,  and  further  treatment  with  steroids  in  the  week  following  the  initial  presentation.  Their
secondary outcome measures were the proportion of subjects requiring admission or salvage therapy, such as nebulised
adrenaline, during the initial presentation. Sparrow and Geelhoed’s [52] trial had similar follow-ups, although in this
trial  the  primary  outcomes  were  different  in  that  the  researchers  wanted  to  know  if  the  children  who  received
prednisolone were more likely to represent for further medical care. Their secondary outcome measures were similar to
that of Fifoot and Ting’s [53] in that they included length of time spent in the emergency department, duration of croup
symptoms (again reported by parents), and use of nebulised adrenaline.
In the studies that looked at longitudinal data to report ‘on-going’ symptoms and need for further treatment for
example, as in Fifoot and Ting’s study [53], it was suggest that the researchers’ methods did not distinguish between
unscheduled re-attendances and planned reviews [20] which made analysis difficult. Despite this, the two studies [52,
53] had good validity with appropriate randomisation, double blinding, and over 85% follow up with similar baseline
characteristics [20]. Parker et al. [55] used a mixture of patient demographics, which included the Westley croup score
and the Geelhoed scoring on presentation to the Emergency department. Fifoot and Ting [53] used modified Taussig
score to assess croup severity. In the Garbutt et al. [54] trial, the researchers use the Westley croup scoring, which was
assessed at the child’s presentation. Sparrow and Geelhoed’s [52] study participants had mild to moderate croup as
defined by clinical symptoms and Taussig croup score.
Parker et al. [55] noted that they found it difficult to discriminate between mild, moderate, or severe retraction from
the notes, thus leading to possible discrepancies in the croup scoring of these children. Inter-rater reliability in this case
would be described as the extent to which two or more people would score or rate things [45].  Parker et al.’s [55]
retrospective  data  on  croup  treatments  is  generally  considered  inferior  to  prospective  designs,  and  which  has  been
recorded for reasons other than research [87]. Another other advantages of conducting chart reviews is its relatively
inexpensive ability to research readily accessible data [66].
A potential problem with data collection through chart reviews in case of Parker et al.’s study [55] was that the
researchers  collected  data  (from a  busy  children’s  ward)  that  may  have  had  the  potential  for  errors  and  inaccurate
recording of symptoms. Intra-observer reliability of the croup scores by clinicians in the Parker et al. trial [55] was re-
assessed by a blinded re-calculation of the scores from 10.6% of the original records selected at random from the initial
data collection using two researchers.  In each group, the extent to which intra-observation agreement was assessed
using a weighted Cohen K score, which in this case was moderate. Intra-observation agreement in the busy practice
setting  of  a  paediatric  emergency  department  showed  the  existence  of  substantial  inter-observer  variability  among
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health care providers in the measurement of respiratory signs associated with croup in young children [88, 89].
Parker et al. [55] recorded measurements of prednisolone’s effectiveness at a thirty-minute mark and thereafter used
this  retrospective  data  to  analyse  the  duration  of  stridor  after  administration  of  steroids  as  determined  by  nursing
observations. Data collected may have been inaccurate due to the busy state of the ward and subject to recall bias, with
the timings rounded up to the nearest 30 minutes. This was a surprising weakness in this study given that the objective
was  to  determine  the  specific  duration  of  stridor.  However,  acknowledging  that  the  trial  was  conducted  in  a  busy
emergency  department,  10-15  minute  observations  may not  have  been  feasible  or  possible.  The  time noted  for  the
cessation of stridor at rest (SAR) relied heavily on researcher’s finding the comment ‘nil stridor at rest’, usually found
in the nursing records. The nursing notes may have been completed sometime after the actual disappearance of the
SAR, and this may have under or overestimated the duration of the symptoms. Results showed that SAR at rest was
well documented in the nursing notes. However, it is suggested that overall figures for calculating stridor are suggested
to be too open to inter-rater variability to be able to accurately describe the severity in each group, i.e. the nurses graded
the child’s symptoms differently.
Other examples of possible inter-rater reliability and intra-observer reliability issues in the trials were found in all
three of the randomised control trials due to which the studies had limitations because the subjective information from
parents/guardians in the follow-up telephone reviews would have relied entirely on the parents accurately describing
their  child’s  symptoms.  Although,  Sparrow  and  Geelhoed’s  [52]  main  outcomes’  measure  was  determined  by
unscheduled re-presentation to medical care, as determined by a telephonic follow-up at 7-10 days, which was less
inclined to erroneous data from parents.
Fifoot and Ting [53] interviewed the parents of 86 patients (87%) in 1 week, asking them to recall symptoms and
further needs for care. Garbutt et al. [54] also collected similar outcomes with telephone interviews on days 1, 2, 3, 4,
and 11. Intra-observer reliability issues that were noted by this particular approach were the potential issues of recall
bias as the information might have been extremely subjective. Information gathered depended entirely on memory,
which can often be  imperfect  and thereby unreliable,  as  in  the  case  of  people  who have difficulty  remembering or
accurately retrieving incidents that happened in the past, leading to poor versions of the original percept. Recall bias is a
classic form of information bias and represents a major threat to the internal validity of studies that use self-reported
data [90].
When considering the factors that might explain any differences in the direction and size of effect seen across the
included studies, further analysis of the studies showed that a proportion of the children treated by Garbutt et al. [54]
(which evaluated three days of treatment with prednisolone (2/mg/kg) versus one dose of dexamethasone for croup)
needed treatment with further steroids at with the same frequency, regardless of the initial treatments assignment. This
concluded that prednisolone at initial presentation and at one and four hours is as effective as dexamethasone. Garbutt et
al. [54] remark that they did not demonstrate whether prednisolone prevents representation after the initial presentation,
thus overall supporting the use of prednisolone for croup. This was disappointing as their three-day trial of prednisolone
was the first of its kind. In contrast, the Sparrow and Geehoeld’s [52] trial reported on unscheduled representation rates
and found that 7% of the dexamethasone group returned for care, whereas 29% of the prednisolone group showed that a
single dose of prednisolone does not work as well as a single dose of dexamethasone for children with mild or moderate
croup. The absolute difference of 22% between the groups had 95% confidence intervals between 8% and 35%, which
was  well  outside  the  authors’  definition  of  equivalence  [52].  Further  analysis  showed  that  dexamethasone  worked
significantly  better  than  prednisolone  (P  <  0.01)  on  this  measure  [52].  Based  on  this  study,  however,  the  authors
recommend that if prednisolone is used, a two-day course of 1-2 mg/kg is probably justified.
In comparison, Fifoot and Ting [53] found no difference between the three groups of prednisolone when compared
to 0.5 mg dexamethasone or 0.6mg dexamethasone, reporting that there were no significant differences in primary or
secondary  outcome  measures.  However,  Johnson  [27]  while  reporting  on  the  Fifoot  and  Ting  study  [53]  proposed
different  findings  as  13%  of  the  dexamethasone  0.15  mg  group  re-attended  a  week  later,  versus  11%  of  the
dexamethasone 0.6% group versus prednisolone 1mg / kg, which equals to 17%. Furthermore, he criticises the trials for
not  reporting  on  the  significance  of  each  dexamethasone  group  alone  versus  prednisone  alone.  Fifoot  & Ting  [53]
disagree, suggesting that both prednisolone at 1 mg/kg and a low dose of dexamethasone (0.15 mg/kg) were found not
to differ  in efficacy.  Children randomised to dexamethasone were significantly less likely to have a return visit/re-
admission than those randomised to prednisolone (RR 0.3, 95% CI 0.2 to 0.6; I2 statistic 0%) [14], which contradicts the
author’s own findings of no significant differences in primary or secondary outcome measures. Johnson (2008) was also
critical  of  both  trials  [52,  53]  as  their  GRADE  analysis  highlighted  they  had  quality  points  being  deducted  for
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incomplete reporting of results, and not carrying out between-group assessments and their inconsistency in reporting of
results.
Parker  et  al.’s  [55]  chart  review  found  that  symptoms  of  croup  recovered  quickly  after  administration  of
prednisolone but did not report on the need for on-going care after the initial treatments as the other trials did. Further
analysis of the chart review data showed statistical analysis of the children’s croup scores, demographics, and cessation
of SAR, concluding that the median time for SAR was 6.5 hours in children who had been given prednisolone.
4.7. External Validity
It is likely that the applicability evaluated in the included studies is representative of, or can be reproduced in, usual
clinical care. This is important and can be seen as a consideration in all the trials presented with the extent to which
external validity is representative of the study population and thus likely to be representative of the general population
[91]. Appraising the applicability of the results of a study is intertwined with the quality of reporting, i.e. the extent to
which an article provides information about the patients, the intervention, and the context of care which is good in all of
the studies. Often there are concerns about generalizability of trials not in secondary or tertiary care when practiced in
primary care. However, we believe that hospital studies would not be any less representative of the types of children
seen or whether the outcomes would be any different from those observed in primary care settings [92], except that the
children may be sicker. External validity in any of the studies presented is not a concern as the randomly selected results
of  the  chart  review  are  selected  from  one  geographical  area  and  it  is  suggested  the  RCTs  are  very  likely  to
representative  of  the  general  population  who  use  the  treatment  [93].
5. SUMMARY OF REVIEW FINDINGS
Four studies [52 - 55] met the inclusion criteria, but they were too heterogeneous to combine in statistical meta-
analysis. Narrative synthesis was undertaken, which suggests that although prednisolone appears as effective when first
given, it is less so for preventing re-presentation. However, because trial sample sizes were small, outcomes measures
and croup scoring methods so different, firm conclusions are difficult, but it appears as a second dose of prednisolone
the following day may be useful. We are unable to state the optimum dosages required.
6. DISCUSSION
Unfortunately,  the  four  studies  included  were  too  heterogeneous  for  statistical  meta-analysis  to  take  place.
Combining studies  that  are  not  similar  can  cause  significant  inaccuracies  in  summary effects  as  well  as  associated
conclusions,  thus  misleading  decision  makers  and  others  [94]  and  so  by  not  attempting  to  combine  them we  have
avoided made this mistake. Variability in the intervention effects being evaluated in the different studies is known as
statistical  heterogeneity,  which  is  a  consequence  of  clinical  or  methodological  diversity  [50].  While  exploring
relationships within the data from this systematic review, there was some difficulty in organising the findings from the
studies and describing patterns across the studies, in terms of the direction of effect and of the size of effects because
the studies measured different outcomes and used differing methods. Measuring outcomes is suggested to be a key
factor in analysis of the trials [25, 28], but there was too much inconsistency in outcomes assessment because of the
different croup scoring scales or worse, no croup scoring, within the studies [52 - 55]. Where secondary outcomes such
as on-going symptoms are vague, this may be due to poor inter-rater reliability [95].
6.1. Clinical Effectiveness
The relatively small sample sizes, heterogeneity of outcomes and effects, and other limitations noted above make
this systemic review limited as a means of indicating clinical effectiveness’ assessing optimum dosages and rates of re-
presentation, which were our original aims. Although three of the studies are RCTs, which might indicate that this body
of evidence sits towards the top of accepted hierarchies of evidence, this systematic review would be rated weak as a
guide for clinical practice [45].
6.2. Grey Literature and Eliminating Bias
A significant  amount  of  time  was  devoted  to  identifying  grey  literature.  Authors  of  the  studies  included  in  the
literature review were written to. A review of the materials found in the reference lists of included studies was also
conducted  by  looking  through  university  theses  as  well  as  by  hand  searching  of  articles,  conferences,  reports,  and
opinion pieces. It is suggested that grey literature is particularly difficult to identify and retrieve with some databases,
A Systematic Review and Comprehensive Critical Analysis The Open Nursing Journal, 2017, Volume 11   255
such as the National Research Register, listing unpublished work [96]. By including unpublished evidence, it may be
possible to minimise the impact of the bias towards publishing only positive results in the literature [97]. The validity of
a systematic review is highly dependent on the results of the underlying data, and the inclusion of grey literature may
help to overcome some of the problems of publication bias, which can arise due to the selective availability of data [98].
The most consistent difference between published and grey literature is that published research is more likely to contain
results that are statistically significant and can contain effect size estimates that are about one-third larger than those of
unpublished studies [99]. Although time-consuming and costly, literature searches which cover the grey literature in all
relevant languages and databases, are normally recommended to prevent reporting biases, but this was not possible in
the systematic review as resources did not allow employment of speakers of languages other than English to conduct
searchers. It is not clear how much this systematic review would be affected by a lack of grey literature in non-English
languages, which is therefore acknowledged as a potential sources of bias. We were not able to construct funnel plots to
assess publication bias due to the small number of studies and their relative heterogeneity, which is a further limitation
of this systematic review.
6.3. Quality of Included Studies
Quality assessment is an integral part of a systematic review because if the results of individual studies are biased,
and these are synthesised without any consideration of quality, then the results of the review will also be biased, and the
quality of the evidence and conclusions generated by a systematic review depends on the quality of the primary studies
that  make  up  the  review  [100,  101].  We  have  included  details  of  our  quality  assessment  processes,  involving
independent assessment by two researchers (AE and GW), and this process gave consideration to the methodological
quality  of  studies,  including  allocation  concealment,  randomisation  and  comparability  of  the  group’s  baseline
characteristics,  treatment adherence and participation and was based on established processes [38].  Trials  with low
methodological quality and small sample sizes can result in misinterpretation of RCT’s overestimated differences in
effectiveness or undetected, smaller, but statistically significant differences, and we have acknowledged these issues in
the detailed critical analysis above. None of the included studies were scored less than 0.6, which is an acceptable cut
off point for inclusion [38]. Higher quality scores should indicate studies with a better methodological quality [47] but
methodological quality is likely to remain relatively subjective, as has been the case in this systematic review.
CONCLUSIONS AND RECOMMENDATIONS
Overall, the evidence from this systematic review seems to suggest that although prednisolone appears as effective
when first given, it is not as good at preventing re-presentation. There continues to be a paucity in the existing literature
as  to  whether  prednisolone  is  as  effective  as  dexamethasone.  Fifoot  and  Ting  [53]  agree  and  also  conclude  that
dexamethasone and prednisone are equally effective when initially given and also are equally effective at preventing
readmission, finding no difference between oral dexamethasone and oral prednisolone in case of croup score at four
hours or in terms of rate of return for medical care [53], although they concluded that at that time there was not enough
evidence either way to conclusively establish that prednisolone is as good, but early on in treatment, i.e. in the first 6
hours, the ‘Stridor at rest’ resolved promptly after prednisolone and was as effective as dexamethasone [55]. Even so,
more investigation is needed to evaluate the comparable efficacy. It is likely that a large proportion of the children, who
would have been previously admitted to the hospital,  would have been treated and discharged from the emergency
department after having prednisolone [55].
The optimum dose of prednisone to prevent relapsing symptoms and readmission is still unclear and requires further
research.  A  comparable  efficacy  between  a  single  dose  of  dexamethasone  and  single  oral  dose  of  prednisolone  (1
mg/kg) for mild to moderate croup has been suggested elsewhere [102], but Garbutt et al. [54] concluded that when a
three-day course of prednisolone is administered, the researchers found this approach to be equivalent to a single oral
dose  of  dexamethasone  (0.6/mg/kg),  once  again  highlighting  that  prednisolone  and  dexamethasone  seem  equally
effective when first given but relapse and re-attendance to medical care is more common with prednisolone in children
with mild or moderate croup, although again there is disagreement about this elsewhere [103]. There is an absence of
evaluative research on prednisolone compared to dexamethasone in respect to repeated doses but also a view that it
would not be palatable [14, 24]. No other studies as yet have compared the effectiveness of dexamethasone and multiple
doses of prednisolone for the treatment of croup in the community setting, but this systematic review indicates that
clinicians might be able to feel confident giving a repeat dose of prednisolone the following day, should the child still
have stridor or other residual symptoms such as a ‘barking cough’, particularly if they are followed up by telephone, as
did Garbutt et al  [54]. Prednisolone is widely regarded as an alternative to dexamethasone for croup [29] but there
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remain questions over the evidence base for dosages: as well as the regimens listed above, UK guidelines suggest a
repeat  dose  of  prednisone  the  following  day,  but  only  if  there  are  residual  symptoms  [14].  The  British  National
Formulary (BNF) [104] only recommend 0.15/mg/kg of dexamethasone and do not recommend prednisolone, unless the
child  has  severe  croup  and  is  being  admitted  to  hospital  where  they  recommend  a  single  dose  of  0.15mg  /  kg
dexamethasone and administer 1-2 mg/ kg of prednisolone when the former is not available. Oral prednisolone at 1-2
mg/kilo is an alternative if dexamethasone is not available but no further advice on repeat dosing is given[1].
There  may  be  a  possible  economic  benefit  to  using  prednisolone,  as  prednisone  is  significantly  cheaper  than
dexamethasone and seems to be more widely available. Besides, soluble prednisolone is probably more widely available
and cheaper than liquid dexamethasone. For treating a 12 kg child, the prednisolone dose would cost £0.75 compared to
£2.50 for 0.15 mg/kg of dexamethasone [104]. Even if a 2-day course of prednisolone is given, it still results in a 40%
cost saving [20], therefore a recommendation of this systematic review is that when further studies are undertaken, cost-
benefit analysis is part of the study design.
More research is needed which examines direct comparison trials of both drugs with sufficient numbers and length
of trials  with appropriate  reliable outcomes of  primary care.  In general,  primary care manages the vast  majority of
children with mild croup, with only one RCT evaluating interventions in true primary care settings [54]. Large trials are
needed that examine single or multi dose of prednisolone at the kind of numbers with which Bjornson et al. [7] used:
this would give clinicians more robust evidence that prednisolone is as effective as dexamethasone in treating croup.
Trials testing a longer course of prednisolone should be done in places where dexamethasone elixir is hard to come by
[35]. There is an argument that those conducting further research studies should standardise their outcome measures, as
a minimum there needs to be some consensus as to whether the Westley or Geelhoed scoring systems, or indeed both,
should be utilised.
This systematic review highlights the most available and up to date research and its methods in this area and on a
practical level, we believe, shows that prednisolone is as effective when first given and that two doses are far more
likely to control symptoms at that level. It is very likely that small, short doses of prednisolone are safe for children,
may  be  well  tolerated  and  improve  symptoms  quickly.  Given  the  data  reviewed,  prednisolone  appears  to  be  an
appropriate choice in the treatment of mild to moderate croup where dexamethasone is not available. It is no longer
reasonable  to  conclude that  the  use  of  corticosteroids  should be  reserved for  individuals  who are  hospitalised with
moderate  to  severe  croup  [3],  with  prednisolone  offering  a  convenient  and  familiar  treatment  for  the  primary  care
management of croup [54].
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